Guardant Health (NASDAQ: GH) is one of 24 publicly-traded companies in the “Medical laboratories” industry, but how does it contrast to its competitors? We will compare Guardant Health to related businesses based on the strength of its earnings, profitability, institutional ownership, dividends, risk, valuation and analyst recommendations.

Valuation & Earnings

This table compares Guardant Health and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Guardant Health $90.64 million -$85.06 million -27.46
Guardant Health Competitors $1.13 billion $64.24 million -1.79

Guardant Health’s competitors have higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Guardant Health and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Guardant Health N/A N/A N/A
Guardant Health Competitors -105.92% -115.51% -34.04%

Institutional & Insider Ownership

69.6% of Guardant Health shares are owned by institutional investors. Comparatively, 52.0% of shares of all “Medical laboratories” companies are owned by institutional investors. 17.1% of shares of all “Medical laboratories” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Guardant Health and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Guardant Health 0 1 4 0 2.80
Guardant Health Competitors 173 627 736 46 2.41

Guardant Health presently has a consensus price target of $72.50, indicating a potential downside of 5.70%. As a group, “Medical laboratories” companies have a potential upside of 14.41%. Given Guardant Health’s competitors higher possible upside, analysts clearly believe Guardant Health has less favorable growth aspects than its competitors.

Guardant Health Company Profile

Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with's FREE daily email newsletter.